LT2500730T - Tirpios formos urokinazės plazminogeno aktyvacijos receptorius (supar) kaip diagnostinis žemo laipsnio uždegimo žymuo - Google Patents

Tirpios formos urokinazės plazminogeno aktyvacijos receptorius (supar) kaip diagnostinis žemo laipsnio uždegimo žymuo

Info

Publication number
LT2500730T
LT2500730T LTEP12164660.8T LT12164660T LT2500730T LT 2500730 T LT2500730 T LT 2500730T LT 12164660 T LT12164660 T LT 12164660T LT 2500730 T LT2500730 T LT 2500730T
Authority
LT
Lithuania
Prior art keywords
supar
low
plasminogen activator
diagnostic marker
urokinase plasminogen
Prior art date
Application number
LTEP12164660.8T
Other languages
English (en)
Inventor
Jesper Eugen-Olsen
Steen B Haugaard
Ove Andersen
Original Assignee
Hvidovre Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hvidovre Hospital filed Critical Hvidovre Hospital
Publication of LT2500730T publication Critical patent/LT2500730T/lt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP12164660.8T 2006-12-22 2007-12-21 Tirpios formos urokinazės plazminogeno aktyvacijos receptorius (supar) kaip diagnostinis žemo laipsnio uždegimo žymuo LT2500730T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87683806P 2006-12-22 2006-12-22
DKPA200601709 2006-12-22
US94707407P 2007-06-29 2007-06-29
DKPA200700956 2007-06-29

Publications (1)

Publication Number Publication Date
LT2500730T true LT2500730T (lt) 2018-05-10

Family

ID=39358030

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12164660.8T LT2500730T (lt) 2006-12-22 2007-12-21 Tirpios formos urokinazės plazminogeno aktyvacijos receptorius (supar) kaip diagnostinis žemo laipsnio uždegimo žymuo

Country Status (15)

Country Link
US (2) US8815519B2 (lt)
EP (2) EP2500730B1 (lt)
AU (1) AU2007337996B2 (lt)
CA (1) CA2674521C (lt)
CY (1) CY1120296T1 (lt)
DK (2) DK2500730T3 (lt)
ES (2) ES2670711T3 (lt)
GB (1) GB2461410C (lt)
HU (1) HUE037758T2 (lt)
LT (1) LT2500730T (lt)
PL (1) PL2500730T3 (lt)
PT (1) PT2500730T (lt)
SI (1) SI2500730T1 (lt)
TR (1) TR201807733T4 (lt)
WO (1) WO2008077958A2 (lt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
ES2457822T3 (es) 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
DK2240781T3 (en) 2008-01-18 2018-03-26 Harvard College METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
CA2779958A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
US8349256B2 (en) * 2008-11-21 2013-01-08 Sysmex Corporation Blood cell analyzer, blood cell analyzing method, and computer program product
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
WO2012012693A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
EP2596134B1 (en) 2010-07-23 2020-04-08 President and Fellows of Harvard College Methods of detecting diseases or conditions using phagocytic cells
JP6055464B2 (ja) 2011-05-09 2016-12-27 ザ ユニバーシティー オブ マイアミ 循環血中の可溶性ウロキナーゼ受容体の低減
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
EP2861788B1 (en) 2012-06-15 2018-10-10 Progenity, Inc. Methods of detecting diseases or conditions using circulating diseased cells
WO2013188846A1 (en) 2012-06-15 2013-12-19 Harry Stylli Methods of detecting diseases or conditions
WO2014012043A1 (en) * 2012-07-13 2014-01-16 Baylor Research Institute Urinary triaosylceramide (gb3) as a risk factor in non-fabry heart disease subjects
US20140188442A1 (en) * 2012-12-27 2014-07-03 Pearson Education, Inc. System and Method for Selecting Predictors for a Student Risk Model
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
MA40636A (fr) 2014-09-11 2015-09-11 Colleen Kelly Procédés pour détecter le cancer de la prostate
US20180146919A1 (en) * 2015-06-16 2018-05-31 Quantum Dental Technologies Inc. System and method of monitoring consumable use based on correlations with diagnostic testing
US20190025328A1 (en) 2015-10-27 2019-01-24 Abbott Laboratories Troponin i and soluble urokinase receptor detection for determining the risk of cardiovascular disease
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
GB201802795D0 (en) * 2018-02-21 2018-04-04 Virogates As Patient assessment method
RU2706548C1 (ru) * 2019-01-31 2019-11-19 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ диагностики стадий вич-инфекции
WO2020206129A1 (en) * 2019-04-02 2020-10-08 The Regents Of The University Of Michigan Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease
CN111128398B (zh) * 2020-03-30 2020-08-14 广州地理研究所 一种基于人口迁徙大数据的流行病感染人数估算方法
WO2021204902A1 (en) 2020-04-08 2021-10-14 Virogates A/S Sars-cov-2 infection risk assessment method
CN112630442A (zh) * 2020-11-03 2021-04-09 浙江大学 一种血浆可溶性尿激酶型纤溶酶原激活物受体及其应用
CA3245469A1 (en) * 2022-03-07 2023-09-14 Rush University Medical Center NEW TREATMENT FOR DIABETES AND KIDNEY DISEASE BY INHIBITION OF THE D2D3 PROTEIN UPAR PROTEOLYTIC
CN114334170A (zh) * 2022-03-14 2022-04-12 天津云检医学检验所有限公司 一种代谢年龄预测模型及其在结直肠癌诊断中的应用
CN114783607B (zh) * 2022-05-10 2023-06-23 中南大学湘雅医院 一种手术输血风险预测模型及其网络计算器的构建方法
CN116106535B (zh) * 2023-04-11 2023-08-11 南京品生医学检验实验室有限公司 生物标志物组合在制备乳腺癌预测产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04506148A (ja) 1989-04-07 1992-10-29 カンサーフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンサーフォースクニング） ウロキナーゼ型プラスミノーゲン活性化因子レセプター
ATE368854T1 (de) * 1999-11-25 2007-08-15 Jesper Eugen-Olsen Verfahren zur diagnose oder prognose einer hiv infektion in einem patienten
US7737256B2 (en) * 2001-01-25 2010-06-15 Fondazione Centro San Raffaele Del Monte Tabor Antibody against uPA/uPAR
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
CN101022830A (zh) 2004-05-25 2007-08-22 阿特努奥恩公司 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases

Also Published As

Publication number Publication date
WO2008077958A2 (en) 2008-07-03
EP2115478A2 (en) 2009-11-11
SI2500730T1 (en) 2018-08-31
US20140370527A1 (en) 2014-12-18
DK2500730T3 (en) 2018-05-28
GB2461410C (en) 2018-06-20
AU2007337996B2 (en) 2013-03-14
GB2461410B (en) 2011-06-29
TR201807733T4 (tr) 2018-06-21
EP2500730B1 (en) 2018-03-07
PT2500730T (pt) 2018-05-28
AU2007337996A1 (en) 2008-07-03
US8815519B2 (en) 2014-08-26
ES2670711T3 (es) 2018-05-31
EP2500730A1 (en) 2012-09-19
US9645157B2 (en) 2017-05-09
DK2115478T3 (en) 2014-03-10
EP2115478B1 (en) 2014-01-22
PL2500730T3 (pl) 2018-08-31
GB2461410A (en) 2010-01-06
ES2456043T3 (es) 2014-04-21
HUE037758T2 (hu) 2018-09-28
CA2674521A1 (en) 2008-07-03
CA2674521C (en) 2022-06-14
WO2008077958A3 (en) 2009-04-02
GB0912351D0 (en) 2009-08-26
CY1120296T1 (el) 2019-07-10
US20100098705A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
LT2500730T (lt) Tirpios formos urokinazės plazminogeno aktyvacijos receptorius (supar) kaip diagnostinis žemo laipsnio uždegimo žymuo
PT2117571T (pt) Resumo
SI2420497T1 (sl) 5-substituirani kinazolinonski derivati kot sredstva proti raku
IL194800A0 (en) Pre-mixed, ready-to-use pharmaceutical compositions
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
IL200854A (en) Converted Spiro Compounds, Methods for their Preparation and Pharmaceutical Compositions Containing Them to Delay New Vascular Formation
EP2504035B8 (en) Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
IL197389A0 (en) Prophylactic or therapeutic agent for cancer
EP2150600A4 (en) USE OF ANY ACID TO PROMOTE THE INCLUSION OF MICRO-NUTRIENTS
IL197983A0 (en) Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
WO2011130537A3 (en) Pharmaceutical compositions and methods for digesting atherosclerotic plaques
WO2010101903A3 (en) Compositions, methods and kits for preparing plasminogen; and plasmin prepared therefrom
PL1978981T3 (pl) Kompozycje do podawania dopochwowo
IL195561A0 (en) Methods and compositions for targeting hepsin
EP2184073A4 (en) AGAINST PROTEASE HEMMER RESISTANT CANCER THERAPEUTICS
EP2150818A4 (en) COMPOSITIONS AND METHOD FOR COMBINING REPORT ANTIBODIES
EP2076144A4 (en) UNTERHOSE
EP2123295A4 (en) THERAPEUTIC AGENT FOR INTERSTITIAL PNEUMONIA
EP1932498A4 (en) INTERLABIAL MATTRESS
SI1911455T1 (sl) Farmacevtski sestavki za topično vaginalno aplikacijo
EP2393936A4 (en) COMPOSITIONS, KITS AND METHODS FOR DETERMINING PLASMINE ACTIVITY
EP2150243A4 (en) COMPOSITIONS AND METHODS FOR REINFORCED ACTIVE SUBSTANCE ABSORPTION
EP2078382A4 (en) PORTAL OF ADMINISTRATION
EP2094871A4 (en) CANCER DIAGNOSTIC METHODS, SYSTEMS, AND COMPOSITIONS
TWM295521U (en) Structure of ties waistband, underwear having germanium effect